Article
Oncology
Ahmet Bilici, Sinan Koca, Mustafa Karaagac, Sabin Goktas Aydin, Emrah Eraslan, Muhammed Ali Kaplan, Birol Ocak, Sema Sezgin Goksu, Semra Paydas, Fahri Akgul, Sumeyye Derin, Yakup Ergun, Emre Yekeduz, Cihan Erol, Deniz Tataroglu Ozyukseler, Atike Gokcen Demiray, Mustafa Karaca, Zeynep Gulsum Guc, Serkan Menekse, Havva Yesil Cinkir, Ozge Gumusay, Abdullah Sakin, Ozlem Ozkul, Hacer Demir, Dilek Erdem, Mehmet Besiroglu, Olcun Umit Unal, Ramazan Acar, Lokman Koral, Suleyman Sahin, Teoman Sakalar, Aykut Bahceci, Ahmet Ozveren, Ulug Mutlu Gunaydin, Mehmet Metin Seker, Veli Sunar, Pinar Dal, Mehmet Artac, Serdar Turhal
Summary: This study retrospectively analyzed the medical records of patients with non-adipocytic metastatic soft tissue sarcoma treated with pazopanib in 37 oncology clinics in Turkey. The results showed that pazopanib is effective and well-tolerated in the treatment of this disease, with better outcomes observed when used earlier and in patients with good performance status.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
P. D. Rowell, P. C. Ferguson, K. M. Tsoi, J. L. Nevin, R. Novak, A. M. Griffin, J. S. Wunder
Summary: This study reviewed the surgical and oncological outcomes of 29 patients with soft tissue sarcoma who underwent bone resection and endoprosthetic reconstruction (EPR) in the lower extremity. It found a high rate of complications associated with this procedure, including infections and reduced overall survival.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Silvia Stacchiotti, Winette T. A. Van der Graaf, Roberta G. Sanfilippo, Sandrine Marreaud, Winan J. Van Houdt, Ian R. Judson, Alessandro Gronchi, Hans Gelderblom, Saskia Litiere, Bernd Kasper
Summary: This retrospective analysis of first-line chemotherapy in intra-abdominal liposarcoma found that anthracycline-based chemotherapy had limited efficacy, while regimens containing ifosfamide showed higher activity, although not statistically significant in a small number of cases. The study provides a benchmark for future trials on new drugs in well-differentiated/dedifferentiated liposarcoma.
Article
Biochemistry & Molecular Biology
Mauro Loi, Giulia Salvatore, Michele Aquilano, Daniela Greto, Cinzia Talamonti, Viola Salvestrini, Maria Elena Melica, Marianna Valzano, Giulio Francolini, Mariangela Sottili, Costanza Santini, Carlotta Becherini, Domenico Andrea Campanacci, Monica Mangoni, Lorenzo Livi
Summary: Trabectedin sensitizes STS cells to radiation therapy by reducing cell survival rate, inhibiting invasiveness, altering cell cycle distribution, and increasing γ-H2AX foci formation. However, it does not have a synergistic effect on DNA damage repair, neoangiogenesis, and the immune system.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
William G. J. Kerrison, Alexander T. J. Lee, Khin Thway, Robin L. Jones, Paul H. Huang
Summary: Immunotherapy in soft tissue sarcoma has become a popular and promising therapeutic strategy, with immune checkpoint inhibitors showing effectiveness in certain subtypes. Combination therapies have also shown enhanced response rates.
Review
Cell Biology
Shadi Hames-Fathi, Steven W. G. Nottley, Nischalan Pillay
Summary: This article reviews recent advances in the diagnosis and treatment of undifferentiated soft tissue sarcoma (USTS), including genomic sequencing, cancer evolution and heterogeneity studies, and immunotherapy. The critical role of pathologists in the diagnosis and treatment of USTS patients is emphasized.
Article
Oncology
Christophe Bergeron, Meriel Jenney, Federica De Corti, Soledad Gallego, Hans Merks, Heidi Glosli, Andrea Ferrari, Dominique Ranchere-Vince, Gian Luca De Salvo, Ilaria Zanetti, Julia Chisholm, Veronique Minard-Colin, Timothy Rogers, Gianni Bisogno
Summary: The study found that 8 courses of VA treatment was effective for low-risk ERMS patients and the combination of 4 courses of IVA with 5 courses of VA also had good results. Although 4 very young patients experienced VOD, careful monitoring for liver toxicity is crucial.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Medicine, General & Internal
Maria Cecilia Cercato, Concetta Elisa Onesti, Sabrina Vari, Gabriella Maggi, Wioletta Faltyn, Serena Ceddia, Irene Terrenato, Virginia Scarinci, Francesca Servoli, Cristina Cenci, Roberto Biagini, Virginia Ferraresi
Summary: This study aimed to evaluate the feasibility and usefulness of a digital narrative diary in the care pathway of patients with bone sarcoma and limb soft tissue sarcoma. The results showed that the diary provided benefits for both patients and healthcare professionals, including increased awareness, improved communication, and deeper knowledge of patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cell Biology
William J. Anderson, Leona A. Doyle
Summary: The 2020 WHO classification of soft tissue and bone tumors incorporates new information gathered in the 7 years since the previous edition, driving further refinements in classification and the development of ancillary diagnostic tests, and introducing several new entities.
Article
Oncology
Chiara Giraudo, Reineke Schoot, Liesbeth Cardoen, Roberto Stramare, Beatrice Coppadoro, Gianni Bisogno, Amine Bouhamama, Bernadette Brennan, Herve J. Brisse, Daniel Orbach, Ana Coma, Pier Luigi Di Paolo, Cindy Fayard, Leigh McDonald, Salma Moalla, Carlo Morosi, Erika Pace, Vivian Tang, Max M. van Noesel, Andrea Ferrari, Rick van Rijn
Summary: This study indicates that the presence of indeterminate pulmonary nodules does not significantly affect the survival of nonmetastatic patients with adult-type non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).
Review
Oncology
Zhenyi Chen, Huayi Huang, Siyuan He, Yi Wang, Lin Cai, Yuanlong Xie
Summary: Fluorescence imaging technology can assist surgeons in judging tumor boundaries and improving the accuracy of surgical resection. This technology is simple, safe, and does not require additional time during surgery.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Argyris C. Hadjimichael, Alexandros Pergaris, Angelos Kaspiris, Athanasios F. Foukas, Stefania Kokkali, Gerasimos Tsourouflis, Stamatios Theocharis
Summary: Musculoskeletal sarcomas are rare heterogeneous malignancies of mesenchymal origin, with two distinct subtypes, bone and soft tissue sarcomas. The EPH/ephrin signaling pathway plays an important role in sarcoma progression, with significant interactions with various normal and abnormal cascades. EPHs and ephrins have potential as candidates for diagnosis, monitoring, and therapy against bone and soft tissue sarcomas.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Stefania Kokkali, Louiza Vini, Anastasia Stergioula, Anastasios Kyriazoglou, Nikolaos Vassos, Ioannis Boukovinas
Summary: Brain metastases in sarcoma patients are rare, often occurring with extracranial metastases. Treatment modalities include whole-brain radiation therapy, chemotherapy, and surgery, but most patients have a short survival period after brain metastases.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Marcos R. Gonzalez, Daniel Karczewski, Angad D. S. Bedi, Hayley Denwood, Santiago A. Lozano-Calderon
Summary: A study of 770 patients undergoing pelvic sarcoma surgery found that the incidence of soft tissue complications within 30 days after surgery was 12.6%. Risk factors for soft tissue complications included age over 30, hematocrit less than 30%, and longer operative time.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Review
Oncology
Kazuhiro Tanaka, Toshifumi Ozaki
Summary: Approximately 40% of bone sarcomas and 60% of soft tissue sarcomas occur in patients aged 65 years and older. Little evidence exists regarding the management of elderly patients with rare sarcomas. Age is a prognostic factor, and surgical resection is the standard therapy for localized sarcomas. Radiation or ion beam therapy may be considered for unresectable sarcomas. Adjuvant chemotherapy for osteosarcoma in elderly patients is not recommended without verification. For advanced osteosarcoma in elderly patients, doxorubicin and/or ifosfamide-based regimens and molecular-targeted therapies are possible options. Adjuvant chemotherapy with doxorubicin and ifosfamide is recommended for high-risk localized soft tissue sarcoma in patients aged 70 years and younger. In elderly patients with advanced soft tissue sarcoma, doxorubicin monotherapy is the standard first-line treatment, and pazopanib can be an alternative. Gemcitabine-based regimens, pazopanib, trabectedin, and eribulin may be options for second-line treatment in elderly patients with advanced soft tissue sarcoma.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Computer Science, Interdisciplinary Applications
Anne Dirkson, Suzan Verberne, Gerard van Oortmerssen, Hans Gelderblom, Wessel Kraaij
Summary: Patients share coping strategies for illnesses in online support groups. Automatic extraction of these strategies from patient discussion groups has not been attempted before. This study introduces a new task that faces challenges such as complex entities, numerous labels, and relations between documents. The authors present an initial ontology for coping strategies and compare two computational solutions for this task. The evaluation results show limited performance, with multi-label classification outperforming named entity recognition with entity linking.
JOURNAL OF BIOMEDICAL INFORMATICS
(2023)
Letter
Pharmacology & Pharmacy
Mirjam de With, Jonathan Knikman, Jan H. M. Schellens, Hans Gelderblom, Annemieke Cats, Henk-Jan Guchelaar, Ron H. J. Mathijssen, Jesse J. Swen, Didier Meulendijks
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
Geert Spierenburg, Floortje G. M. Verspoor, Jay S. Wunder, Anthony M. Griffin, Peter C. Ferguson, Matthew T. Houdek, David M. King, Richard Boyle, Robert Lor Randall, Steven W. Thorpe, Jacob I. Priester, Erik J. Geiger, Lizz van der Heijden, Nicholas M. Bernthal, Bart H. W. B. Schreuder, Hans Gelderblom, Michiel A. J. van de Sande
Summary: This study compared the short-term postoperative outcomes of one-stage and two-stage surgeries on both sides for diffuse-type tenosynovial giant cell tumors (D-TGCTs) of the knee. The results showed that one-stage surgery did not impair rehabilitation, and patients had a shorter hospital stay and no more complications.
Article
Pharmacology & Pharmacy
Maryam Lyousoufi, Iris Lafeber, Dinemarie Kweekel, Brenda C. M. de Winter, Jesse J. J. Swen, Paul P. H. Le Brun, Erica C. M. Bijleveld-Olierook, Teun van Gelder, Henk-Jan Guchelaar, Dirk Jan A. R. Moes, Kirsten J. M. Schimmel
Summary: Personalized medicine lacks flexible drug formulations, especially for pediatric patients. This study investigates the feasibility of developing a 3D-printed tablet formulation at the point-of-care that complies with quality requirements for clinical practice, including bioequivalence.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Summary: This study is a phase 2 basket trial evaluating the efficacy and safety of dabrafenib plus trametinib in patients with BRAFV600E-mutated advanced rare cancers. The overall response rates in different tumor types ranged from 56% to 89%. Secondary endpoints included duration of response, progression-free survival, overall survival, and safety.
Article
Oncology
Rieneke T. Lugtenberg, Stefanie de Groot, Danny Houtsma, Vincent O. Dezentje, Annelie J. E. Vulink, Maarten J. Fischer, Johanneke E. A. Portielje, Jacobus J. M. van der Hoeven, Hans Gelderblom, Hanno Pijl, Judith R. Kroep
Summary: Docetaxel, an anti-cancer agent, can cause hypersensitivity reactions and fluid retention. High-dose corticosteroids, such as dexamethasone, have been used to reduce these adverse effects, but there is little evidence to support this practice and high doses of corticosteroids can have undesirable effects. This study aimed to evaluate the impact of reducing the dose of dexamethasone on the incidence of hypersensitivity reactions and fluid retention in patients with breast or prostate cancer.
Article
Oncology
Florence Duffaud, Jean-Yves Blay, Axel Le Cesne, Christine Chevreau, Pascaline Boudou-Rouquette, Elsa Kalbacher, Nicolas Penel, Christophe Perrin, Valerie Laurence, Emmanuelle Bompas, Esma Saada-Bouzid, Corinne Delcambre, Francois Bertucci, Mathilde Cancel, Camille Schiffler, Laure Monard, Corinne Bouvier, Vincent Vidal, Nathalie Gaspar, Sylvie Chabaud
Summary: Although the primary endpoint was not met statistically in this randomised cohort, there is evidence to suggest that regorafenib might modestly delay tumour progression in relapsed ES after failure of prior chemotherapy.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Hans Gelderblom, Robin L. Jones, Jean-Yves Blay, Suzanne George, Margaret von Mehren, John R. Zalcberg, Yoon-Koo Kang, Albiruni Abdul Razak, Jonathan Trent, Steven Attia, Axel Le Cesne, Brittany L. Siontis, David Goldstein, Kjetil Boye, Cesar Sanchez, Neeltje Steeghs, Piotr Rutkowski, Mihaela Druta, Cesar Serrano, Neeta Somaiah, Ping Chi, Brooke Harrow, Claus Becker, William Reichmann, Matthew L. Sherman, Rodrigo Ruiz-Soto, Michael C. Heinrich, INTRIGUE Investigators
Summary: In the INTRIGUE trial, there was no significant difference in progression-free survival between ripretinib and sunitinib for advanced gastrointestinal stromal tumour (GIST) patients. The study compared the impact of these treatments on health-related quality of life (HRQoL) and found that patients receiving ripretinib had better HRQoL during the dosing period compared to patients receiving sunitinib.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Philip Heesen, Andreas Ranft, Vivek Bhadri, Benedicte Brichard, Stephane Collaud, Sona Cyprova, Hans Eich, Torben Ek, Hans Gelderblom, Jendrik Hardes, Lianne Haveman, Susanne Jabar, Wolfgang Hartmann, Dimosthenis Andreou, Peter Hauser, Josephine Kersting, Heribert Juergens, Jukka Kanerva, Thomas Kuehne, Anna Raciborska, Jelena Rascon, Arne Streitbuerger, Beate Timmermann, Yasmin Uhlenbruch, Uta Dirksen
Summary: This study analyzed the association between local therapy and event-free survival (EFS), overall survival (OS), and local recurrence (LR) in patients with Ewing sarcoma. The results showed that in certain situations, combination therapy with radiotherapy and surgery can improve the prognosis of patients. This provides important evidence for the personalized treatment of Ewing sarcoma.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
William D. Tap, Maitreyi G. Sharma, Marc Vallee, Bryan D. Smith, Matthew L. Sherman, Rodrigo Ruiz-Soto, Michiel van de Sande, R. Lor Randall, Nicholas M. Bernthal, Hans Gelderblom
Summary: TGCT is a rare neoplasm caused by upregulation of the CSF1 gene. Vimseltinib, an oral tyrosine kinase inhibitor, is being tested in the Phase III MOTION trial for its efficacy and safety in TGCT patients who are not suitable for surgery. Participants will receive vimseltinib or placebo in Part 1, followed by open-label vimseltinib treatment in Part 2.
Editorial Material
Pharmacology & Pharmacy
Sofia L. J. Peeters, Maarten J. Deenen, Anna M. J. Thijs, Emma C. Hulshof, Ron H. J. Mathijssen, Hans Gelderblom, Henk-Jan Guchelaar, Jesse J. Swen
Review
Oncology
J. -y. Blay, M. von Mehren, R. L. Jones, J. Martin-Broto, S. Stacchiotti, S. Bauer, H. Gelderblom, D. Orbach, N. Hindi, A. Dei Tos, M. Nathenson
Summary: Synovial sarcoma is a rare and aggressive disease, accounting for 5%-10% of all soft tissue sarcomas. Diagnosis is often challenging, but referral to a specialist center is crucial for optimal outcomes. Treatment strategies for localized disease include surgery, radiotherapy, and chemotherapy, while advanced disease has a poor prognosis and requires novel management strategies such as targeted agents and immunotherapies.
Article
Oncology
J. Y. Blay, C. Cropet, S. Mansard, Y. Loriot, C. De La Fouchardiere, J. Haroche, D. Topart, D. Tougeron, B. You, A. Italiano, V. Le Brun-Ly, J. M. Ferrero, N. Penel, M. Fabbro, X. Troussard, D. Malka, I. Ray-Coquard, S. Leboulleux, A. Flechon, E. Maubec, J. Charles, S. Dalle, S. Taieb, G. C. T. E. Garcia, A. M. Mandache, N. Colignon, M. Gavrel, F. Nowak, N. Hoog Labouret, C. Mahier Ait Oukhatar, C. Gomez-Roca
Summary: Vemurafenib demonstrates efficacy and prolonged PFS in advanced tumors with BRAF mutations other than melanoma and NSCLC. This therapy is effective for various tumor types including HCL, ECD, ovarian carcinoma, gliomas, ganglioglioma, and sarcomas.
Article
Oncology
Emanuela Palmerini, John H. Healey, Nicholas M. Bernthal, Sebastian Bauer, Hendrik Schreuder, Andreas Leithner, Javier Martin-Broto, Francois Gouin, Julio Lopez-Bastida, Hans Gelderblom, Eric L. Staals, Florence Mercier, Petra Laeis, Xin Ye, Michiel van de Sande
Summary: This study investigated the impact of diffuse-type Tenosynovial giant cell tumor (D-TGCT) on treatment strategies and quality of life for patients. The results showed that patients who switched to an active treatment strategy had higher scores for pain and interference, while patients who remained off-treatment had lower scores at the 2-year follow-up. These findings are important for guiding the treatment and management of D-TGCT.